Enfortumab verdotin (EV), a Nectin-4-targeted antibody conjugated with the microtubule disrupting agent monomethyl auristatin E (MMAE), has demonstrated excellent response rates in locally advanced bladder cancer [8, 6, 9]. The gene discussed is NECTIN4; the disease is urinary bladder cancer.